Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy (NCT07600177)
🩺 Plain-English Summary (8th-Grade Level)
This is an investigator-initiated two-center study. The goal of this study is to investigate the feasibility, safety and efficacy outcomes of a seamless transition from mavacamten to aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM).
Who can join: Review the eligibility criteria below.
Location: St. Luke's Hospital - Mid America Heart Institute — Kansas City, Missouri
Age range: 18 Years to 90 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- St. Luke's Hospital - Mid America Heart Institute — Kansas City, Missouri
- Oregon Health & Science University — Portland, Oregon
📞 Contact the Study Coordinator
Phone: (503) 494-7551
Email: masria@ohsu.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hypertrophic Cardiomyopathy (HCM)
- Perfusion Abnormalities in Hypertrophic Cardiomyopathy — Charlottesville, Virginia
- COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) — Durham, North Carolina
- Large Language Models To Improve the Quality of Care of Cardiology Patients — Palo Alto, California
- HCMR Re-Imaging Study — Evanston, Illinois
Explore by condition: All Hypertrophic Cardiomyopathy (HCM) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.